跳轉至內容
Merck
全部照片(1)

重要文件

1067704

USP

Betamethasone dipropionate

United States Pharmacopeia (USP) Reference Standard

同義詞:

Betamethasone 17,21-dipropionate, 9α-Fluoro-16β-methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione 17,21-dipropionate

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C28H37FO7
CAS號碼:
分子量::
504.59
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

betamethasone

製造商/商標名

USP

應用

pharmaceutical (small molecule)

形式

neat

SMILES 字串

[H][C@@]12C[C@H](C)[C@](OC(=O)CCl)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)C3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

1S/C27H34ClFO7/c1-5-22(33)35-14-21(32)27(36-23(34)13-28)15(2)10-19-18-7-6-16-11-17(30)8-9-24(16,3)26(18,29)20(31)12-25(19,27)4/h8-9,11,15,18-20,31H,5-7,10,12-14H2,1-4H3/t15-,18-,19-,20-,24-,25-,26?,27-/m0/s1

InChI 密鑰

UOCNBCVPZWLUKX-HOBFILNXSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用


  • Efficacy in Alopecia Areata Treatment: A study compared the effectiveness of topical betamethasone dipropionate with minoxidil in treating alopecia areata, highlighting its potent anti-inflammatory properties and its role in promoting hair regrowth. This positions betamethasone dipropionate as a key component in dermatological research aimed at understanding and improving treatment modalities for hair loss conditions (Aslam et al., 2024).

  • Post-Surgical Pain Management: Research demonstrated the utility of a cocktail containing betamethasone dipropionate in reducing pain and prolonging analgesic effects post-total knee arthroplasty. This study emphasizes the pharmacokinetic benefits of betamethasone dipropionate in clinical pain management, providing valuable insights for ongoing pharmacological innovations (Luo et al., 2024).

  • Improvement in Plaque Psoriasis: Betamethasone dipropionate was analyzed for its effectiveness in treating plaque psoriasis when used as part of a calcipotriol/betamethasone aerosol foam. The results underscore its significant role as a glucocorticoid receptor agonist, enhancing therapeutic outcomes for patients with psoriasis, thereby solidifying its place in anti-inflammatory steroid studies and psoriasis treatment compounds (Gerdes et al., 2024).

生化/生理作用

Betamethasone 17,21-dipropionate is a glucocorticoid with anti-inflammatory and immunosuppressive activity.

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

相關產品

產品號碼
描述
訂價

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Repr. 1B - STOT RE 2

標靶器官

Liver,Kidney,Endocrine system

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Sally A Helmy et al.
Therapeutic drug monitoring, 36(1), 100-107 (2013-11-26)
Diflunisal, naproxen, ketoprofen, etodolac, mefenamic acid, rofecoxib, and celecoxib are nonsteroidal anti-inflammatory drugs, which have analgesics, antipyretics, and anti-inflammatory activities. The aim of this work was to develop and validate a simple assay that could be implemented in most laboratories
Lawrence F Eichenfield et al.
Pediatric dermatology, 32(1), 28-35 (2014-11-22)
The objective of this study was to assess the safety and efficacy of the fixed combination calcipotriene 0.005% plus betamethasone dipropionate 0.064% topical suspension in adolescents with extensive scalp psoriasis. In this phase II, open-label, 8-week study, adolescents with psoriasis
Hanne Norsgaard et al.
Archives of dermatological research, 306(8), 719-729 (2014-07-17)
The calcipotriol/betamethasone dipropionate fixed-combination gel is widely used for topical treatment of psoriasis vulgaris. It has been hypothesized that calcipotriol counteracts glucocorticoid-induced skin atrophy which is associated with changes in the extracellular matrix (ECM). To elucidate the combined effects of
Paul L McCormack
Drugs, 71(6), 709-730 (2011-04-21)
Calcipotriol/betamethasone dipropionate (calcipotriol 50 μg/g and betamethasone 0.5 mg/g) is a fixed-dose combination of a vitamin D(3) analogue and a corticosteroid indicated for the once-daily, topical treatment of psoriasis vulgaris of the trunk, limbs and scalp in adults. Both the ointment (Daivobet®;
Julia M Bottomley et al.
Current medical research and opinion, 27(1), 251-268 (2010-12-15)
To evaluate the two-compound formulation (TCF) calcipotriol and betamethasone dipropionate (BDP) gel versus other topical therapies for scalp psoriasis in adults using direct and indirect comparisons. A systematic review identified 10 randomised controlled trials (RCTs) of topical treatments used in

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務